Literature DB >> 1902547

Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma.

M Griebel1, H S Friedman, E C Halperin, M D Wiener, L Marks, W J Oakes, J M Hoffman, G R DeLong, S C Schold, B Hockenberger.   

Abstract

Two patients with brain stem gliomas were treated with hyperfractionated radiation therapy (HFR) (7,020 and 7,560 cGy, respectively). Despite initial clinical improvement during irradiation, both patients demonstrated clinical deterioration approximately 3 weeks after completion of radiotherapy. Cranial magnetic resonance imaging (MRI) revealed a progressive increase in distribution of abnormal brain stem signal consistent with either tumor or edema. 18FDG positron emission tomography (PET) was obtained in one patient and demonstrated a hypermetabolic lesion at diagnosis and a hypometabolic lesion at the time of clinical deterioration postirradiation. Management with a tapering dose of dexamethasone alone resulted in marked clinical (both patients) and radiographic (one patient) improvement, allowing reduction or discontinuation of this medication. These results suggest that patients with brain stem tumors demonstrating clinical and radiographic evidence of progressive tumor shortly after completion of HFR should be initially managed conservatively with dexamethasone, since these findings may be manifestations of reversible radiation-related neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1902547     DOI: 10.1002/mpo.2950190307

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  6 in total

Review 1.  New advances that enable identification of glioblastoma recurrence.

Authors:  Isaac Yang; Manish K Aghi
Journal:  Nat Rev Clin Oncol       Date:  2009-10-06       Impact factor: 66.675

Review 2.  Pros and cons of current brain tumor imaging.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Martin J van den Bent; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

3.  Spurious progression in pediatric brain tumors.

Authors:  Sheema Chawla; David N Korones; Michael T Milano; Ali Hussain; Abdel R Hussien; Ann G Muhs; Manisha Mangla; Howard Silberstein; Sven Ekholm; Louis S Constine
Journal:  J Neurooncol       Date:  2012-01-12       Impact factor: 4.130

4.  Pseudoprogression in boron neutron capture therapy for malignant gliomas and meningiomas.

Authors:  Shin-Ichi Miyatake; Shinji Kawabata; Naosuke Nonoguchi; Kunio Yokoyama; Toshihiko Kuroiwa; Hideki Matsui; Koji Ono
Journal:  Neuro Oncol       Date:  2009-03-16       Impact factor: 12.300

Review 5.  Postradiation imaging changes in the CNS: how can we differentiate between treatment effect and disease progression?

Authors:  Amanda J Walker; Jake Ruzevick; Ashkan A Malayeri; Daniele Rigamonti; Michael Lim; Kristin J Redmond; Lawrence Kleinberg
Journal:  Future Oncol       Date:  2014-05       Impact factor: 3.404

Review 6.  Malignant gliomas: old and new systemic treatment approaches.

Authors:  Tanja Mesti; Janja Ocvirk
Journal:  Radiol Oncol       Date:  2016-04-23       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.